Background: Variation in alcohol metabolism affects the duration of intoxication and alcohol use. While the majority of genetic association studies investigating variation in alcohol metabolism have focused on polymorphisms in alcohol or aldehyde dehydrogenases, we have now tested for association with genes in alternative metabolic pathways that catalyze the carbon skeleton of ethanol (EtOH) and NADH reoxidation.
I
NTERINDIVIDUAL VARIATION IN the absorption and elimination of alcohol (ethanol [EtOH] ) has been shown to be significantly heritable (Kopun and Propping, 1977; Martin et al., 1985; Vesell et al., 1971) . Genes or loci affecting in vivo EtOH metabolism have been identified through linkage and candidate gene association studies. The majority of these studies have focused on enzymes that catalyze the first step of EtOH oxidation to acetaldehyde, namely alcohol dehydrogenases (ADHs) (Birley et al., 2005 (Birley et al., , 2008 (Birley et al., , 2009 , and the second step in which aldehyde dehydrogenase 2 (ALDH2) converts acetaldehyde to acetate (Kiyoshi et al., 2009; Yoshida, 1992) . Genetic variation in ADH1B and ALDH2 is associated with individual and ethnic differences in alcohol consumption patterns Neumark et al., 1998; Raimondi et al., 2004; Whitfield et al., 1998) and risk for alcohol dependence (Edenberg et al., 2006; Kuo et al., 2008; Luo et al., 2006) and alcohol-related cancers (Hashibe et al., 2008) , raising the possibility that genetic variation affecting alcohol metabolism through other enzymes or transporters could also affect these diseases.
Other pathways and genes that catalyze conversion of EtOH to acetaldehyde are the Microsomal EtOH-Oxidizing System (MEOS; via CYP2E1) and catalase (CAT), but they have been estimated to account for <10% of total alcohol metabolism in the body (Agarwal, 2001; Deng and Deitrich, 2008; Lieber, 1999) . Known variants in ADHs and ALDH2 cannot account for the heritability of metabolism, estimated at 50 to 60% from twin studies (Martin et al., 1985) ; variation in downstream events may also be significant (see Fig. 1 ). First, the carbon skeleton of acetate is further metabolized to Acetyl CoA by Acyl-CoA synthetase short-chain family member 1 or 2 (ACSS1, ACSS2) or can be incorporated into the gluconeogenesis pathway as a carbohydrate source by ACN9 (Dennis and McCammon, 1999) . Second, the actions of both ADH (in the cytosol) and ALDH2 (in mitochondria) require the transfer of hydrogen atoms to the oxidized form of nicotinamide adenine dinucleotide (NAD + ), resulting in its reduction to NADH. As mitochondria (which regenerate NAD + from NADH in oxidative phosphorylation) are not permeable to NADH, the bidirectional malate-aspartate shuttle transports the reducing equivalents of NADH between the cytosol and the mitochondria via aspartate-glutamate transporters (SLC25A12 and SLC25A13) and malate carriers (SLC25A10, SLC25A11) (Borst, 1963) . Within the shuttle, cytoplasmic (GOT1) and mitochondrial (GOT2) aspartate aminotransferases catalyze the interconversion of aspartate and a-ketoglutarate to oxaloacetate and glutamate. Similarly, cytoplasmic (MDH1) and mitochondrial (MDH2) malate dehydrogenases catalyze the interconversion of oxaloacetate and NADH to malate and NAD + . The NADH/ NAD ratio is important as excess NADH decreases ADH activity and alters the cellular redox state; reoxidation of NADH has been hypothesized as the rate-limiting step in EtOH oxidation in the liver (Lindros et al., 1972; Meijer et al., 1975) . Furthermore, an increased NADH/NAD ratio affects other substrate couples and produces metabolic changes which are linked with disorders including gout and fatty liver (Lieber, 2003) .
Rather than limiting our analysis to the well-characterized alcohol metabolizing ADH and ALDH2 genes, we have extended our previous studies on these enzymes (Birley et al., 2008 (Birley et al., , 2009 Dickson et al., 2006) to systematically analyze genetic variation in other genes (i) involved in the early steps of EtOH oxidation to acetaldehyde and acetate (ALDH1A1, CAT, CYP2E1); (ii) that play a role in the metabolism of the carbon skeleton of EtOH (ACN9, ACSS1, ACSS2); and (iii) within the malate-aspartate NADH shuttle (GOT1, GOT2, MDH1, MDH2, SLC25A10, SLC25A11, SLC25A12, SLC25A13). This paper reports on the associations of 950 single nucleotide polymorphisms (SNPs) with a series of in vivo alcohol metabolism measures in 352 participants from the Alcohol Challenge Twin Study (ACTS; Martin et al., 1985) , specifically blood alcohol concentration (BAC) and breath alcohol concentration (BrAC), the rates of alcohol absorption and alcohol elimination in the blood and breath, and the peak BAC and BrAC achieved following alcohol challenge.
MATERIALS AND METHODS

Samples
Four hundred and twelve people (206 pairs of twins) participated in the original ACTS between 1979 and 1981 (Martin et al., 1985 . Twin participants were 51.7% female and comprised 85 monozygotic (MZ) twin pairs (43 female and 42 male) and 121 dizygotic (DZ) twin pairs (44 female, 38 male, and 39 opposite sex). Selfreported ancestry of the ACTS participants is predominantly Northern European (87%) with information available on the birthplace of their 4 grandparents. The twins ranged in age from 18 to 34 years (mean age: 23.0 ± 4.6) at the time of testing with 70% of subjects aged <25 years. Twins were recontacted 10 to 20 years after completion of the ACTS to obtain DNA for genotyping and blood samples were collected from 372 twins. Subjects gave written informed consent and genetic studies were approved by the Queensland Institute of Medical Research (QIMR) Human Research Table 2 .
Ethics Committee. Zygosity of same-sex twin pairs was assessed using a combination of self-report, blood groups, and a set of 9 polymorphic DNA microsatellite markers (AmpF1STR Profiler Plus Amplification Kit; Applied Biosystems, Foster City, CA).
Measures
BAC and BrAC (expressed as mg per 100 ml of blood) was recorded following ingestion of a weight-related dose of EtOH (0.75 g/kg) over 20 minutes. Full details are given in Martin and colleagues (1985) and a summary of the phenotypes analyzed in the current study is given in Table 1 . Six timed measurements of BAC (LP1-LP6; over 3.5 hours) and 10 of BrAC (RP01-RP10; over 5.5 hours) were obtained starting 40 minutes after the commencement of EtOH intake. Owing to changes in the sampling schedule over the duration of the ACTS, occasional delays in taking blood samples and missing samplings, values were predicted for each individual at the 6 mean observation times for BAC and 10 mean observation times for BrAC. A curve was fitted to the predicted BACs and BrACs for each subject; the rate of absorption, peak concentration, and rate of elimination were calculated for blood (BLAP, PKLP, BLEP, respectively) and breath (BRAP, PKRP, BREP) separately. Correlations between observed and predicted BACs and BrACs at all sampling times were >0.92, and variances of predicted BACs and BrACs were lower than those of the corresponding observed readings consistent with a reduction in error variance.
SNP Selection
Data for 950 SNPs from 14 candidate genes were obtained from 2 data sets: a candidate gene study (using Sequenom iPLEX genotyping chemistry) and a genome-wide association study (GWAS) using Illumina BeadChips. The genes and number of SNPs genotyped and analyzed are summarized in Fig. 1 and Table 2 , respectively.
The candidate gene study was conceived in December 2007, carried out in 2 stages and completed in 2009. A total of 132 SNPs from 12 genes were selected based on the information available at the time from published literature (Dick et al., 2008; Webb et al., 2011) , in addition to common (minor allele frequency [MAF] > 5%) synonymous or nonsynonymous SNPs and tag SNPs selected from genotype data downloaded from the International HapMap Project public database using NCBI Build 35 (Stage 1; ACN9, ACSS2, CYP2E1, SLC25A13) and NCBI Build 36 (Stage 2; ACSS1, GOT1, GOT2, MDH1, MDH2, SLC25A10, SLC25A11, SLC25A12) and Haploview version 4.0 software (http://www.broadinstitute.org/ scientific-community/science/programs/medical-and-populationgenetics/haploview/haploview; Barrett et al., 2005) .
Imputed genotypes from the GWAS data set were extracted for all SNPs (N = 936) within a fixed 20 Kb gene border for each of the 12 candidate genes above plus ALDH1A1 and CAT using gene coordinates downloaded from the University of California, Santa Cruz table browser for all RefSeq genes on July 24, 2008.
Genotyping
Sequenom Platform. Assays were designed using the Mass ARRAY Assay Design (version 3.0) software (Sequenom Inc., San Diego, CA) and typed using iPLEX chemistry on a Compact MALDI-TOF Mass Spectrometer (Sequenom Inc.). Primers were purchased from Bioneer Corporation (Daejeon, Korea). Genotyping was carried out in standard 384-well plates with 12.5 ng genomic DNA used per sample and allele calls were reviewed using the cluster tool in the SpectroTyper software (Sequenom Inc.).
Illumina Platform. Genotype data for 275 ACTS twins (352 if including 77 imputed MZ co-twins) were drawn from 4 of 9 GWAS subsamples (N = 17,862 individuals) genotyped for the Genetic Epidemiology laboratory at QIMR using Illumina HumanCNV370-Quadv3 (N = 223), Human610-Quadv1 (N = 36), and 317 K (N = 16) BeadChips. Standard QC filters were applied and have been described elsewhere (Medland et al., 2009) . A consensus marker set (N = 269,840 SNPs) was imputed up to 2,380,486 HapMap SNPs (The International HapMap Consortium, 2003) using the Mach (Li and Abecasis, 2006) program, as described by Medland and colleagues (2009) . Samples were screened for ancestry outliers and individuals were excluded who were >2 standard deviations from the PC1 and PC2 centroid derived from European populations following Eigenstrat analysis .
Imputation QC measures for 818 of 936 SNPs are summarized in Table S1 . Imputed genotypes for 118 SNPs typed in the candidate gene study were not included in the joint data set. On average the genotype discordance rate for the 118 duplicated SNPs was 2.4% and is summarized in Table S2 . The genotype data for ACSS1 and SLC25A10 SNPs showed the strongest discordance rates on average with 4.39% (range, 0 to 7.9%) and 4.33% (range, 0 to 24.5%), respectively.
Statistical Analysis
We tested whether 950 SNPs were associated with (i) 6 BAC [LP1-LP6] and 10 BrAC [RP01-RP10] measurements; (ii) rate of alcohol absorption (BLAP, BRAP); (iii) rate of alcohol elimination (BLEP, BREP); and (iv) peak alcohol concentration in the blood and breath (PKLP, PKRP). Tests of total association with each quantitative trait at each marker were performed in QTDT (Abecasis et al., 2000) . Total association considers transmission within and between families, specifying an additive model against the null hypothesis of no linkage and no association (Table S3) . The between-family association component is not robust to population stratification. Therefore, additional analyses in QTDT were performed to check for population stratification by using a variant of the orthogonal model which evaluates population stratification by comparing the between-and within-family components of association (Table S4) . QTDT takes into account familial relatedness and zygosity, with the trait values of MZ twins averaged across the pair. All quantitative traits were transformed to normality using inverse rank normal transformation. Correction for sex, age, age 2 , sex 9 age, and sex 9 age 2 was performed by fitting covariates in the regression model. Phenotypes were also adjusted for possible effects of population stratification in our sample by fitting the first 10 eigenvectors (PC1-PC10) from European-only principal components analysis of ancestry in the regression model . Sequenom genotype data and phenotypes were available for 366 twins (40.0% male) from 187 families comprising 77 MZ pairs (42 female and 35 male), 102 DZ pairs (37 female, 27 male, and 38 opposite sex), and 8 unpaired DZ twins. Imputed GWAS data and phenotypes were available for 275 twins (45.5% male) from 191 families comprising 77 MZ twins (40 female and 37 male), 84 DZ pairs (34 female, 23 male, and 27 opposite sex), and 30 unpaired DZ twins. Two SNPs (rs11190090 and rs17850882) were found to be monomorphic.
To calculate the study-wide threshold of significance, the multiple correlated SNPs and phenotypes tested must first be corrected for. Reflecting moderate linkage disequilibrium (LD) across many of the candidate genes, the effective number of independent SNPs tested was 208, as determined by SNPSpD (Nyholt, 2004) . Likewise, the effective number of independent phenotypes was calculated to be 6.0003 in matSpD (http://gump.qimr.edu.au/general/ daleN/matSpD/) (Nyholt, 2004) . Therefore, a conservative p-value <4.01 9 10 À5 (0.05/208 SNPs/6 traits) would be required for study-wide significance. We have 96% and 37.0% power (a = 0.05) to detect overall association with an SNP (with MAF above 0.01) which explains 5% and 1%, respectively, of variance in our trait under an additive model and against a background sibling correlation of 0.30 (Purcell et al., 2003) . Power is reduced to 33.5% for an SNP explaining 5% of variance when a = 4.01 9 10 À5 (the study-wide significance threshold); to achieve 80% power, a sample size of 477 would be required. The sample size required to achieve 80% power increases to 1,304 for an SNP explaining 1% of variance.
To account for the multiple correlated BAC and BrAC phenotypes (see Table S5 for correlations), we also employed the MQFAM multivariate extension in PLINK 1.06 (Ferreira and Purcell, 2009 ) to test for association between individual SNPs and (i) all BAC levels; (ii) early BACs (LP1-LP3); (iii) late BACs (LP4-LP6); (iv) all BrAC levels; (v) early BrAC levels (RP01-RP05); and (vi) late BrACs (RP06-RP10) (Table S6) . For these analyses, standardized residuals adjusting for sex, age, sex 9 age, age 2 , and sex 9 age 2 and PC1-PC10 eigenvectors for each measurement were calculated before submission to MQFAM. Trait values of MZ twins were averaged across the pair. Permutation testing within MQFAM was used to correct for family structure. For the multivariate analyses, the study-wide level of significance is 4.01 9 10 À5 (0.05/208 SNPs 9 6 traits).
RESULTS
Descriptive
With a combined set of in-house genotyping and imputed GWAS markers, a total of 950 SNPs spanning 14 candidate genes were analyzed. No marker showed significant departures from Hardy-Weinberg equilibrium (p < 0.001). We first conducted analyses of blood alcohol measures and then breath alcohol measures obtained during the alcohol challenge. Total association results for all SNPs and blood and breath phenotypes are presented in Table S3 and Figs S1-S3.
Allelic Effects on Blood Alcohol Concentration
Tests of total association were conducted for each SNP with all 6 BAC levels (LP1-LP6), as well as the rate of alcohol absorption into the blood (BLAP), rate of alcohol elimination (BLEP), and the peak BAC (PKLP). Twenty-three SNPs associated with one or more of these blood alcohol phenotypes at a significance level of p < 0.005 are summarized in Table 3 (rs348447 in the ALDH1A1 promoter was affected by population stratification). The strongest evidence of association with blood alcohol metabolism was observed with SNPs in CYP2E1 and ALDH1A1. One SNP, rs4838767, in the promoter of CYP2E1 exceeded the threshold for study-wide significance (4.01 9 10 À5 ) for 2 blood alcohol measures tested (LP1 and LP2). Six study participants (1 male MZ twin pair, 1 female DZ twin pair, and 2 unrelated twins) were observed to be heterozygous (A/C) for this rare CYP2E1 promoter SNP (MAF = 0.008) that was primarily associated with the earlier times LP1-LP3 (p < 0.00007) and the peak BAC (p = 0.0007). A second CYP2E1 SNP (rs4646976) in moderate LD (r 2 = 0.748) with rs4838767 was most associated with LP1-LP3 measures (p < 0.001) and the rate of blood alcohol elimination (BLEP, p = 0.0004). Four intronic ALDH1A1 SNPs in moderate to high LD (rs2017362, rs348461, rs348463, and rs2210103) were strongly associated with late BAC readings LP4-LP6 (p < 0.003). A nonsynonymous coding polymorphism, rs238239, in exon 5 of enolase 3 (ENO3), near SLC25A11, was associated with LP1 (p = 0.0043), as well as the rate of blood alcohol absorption (BLAP; p = 0.0029).
Allelic Effects on Breath Alcohol Concentration
Total association analyses were conducted for 10 BrAC levels (RP01-RP10), as well as the rate of alcohol absorption in the breath (BRAP), rate of alcohol elimination (BREP), and the peak BrAC (PKRP). Seventeen SNPs associated with one or more of these phenotypes at a significance level of p < 0.005 are summarized in Table 4 . The rs238247 SNP in the SLC25A11 candidate region showed evidence of population stratification for 5 BrAC levels (RP06-RP10).
The most associated SNP (rs4838767) with the breath alcohol metabolism variables is the CYP2E1 promoter SNP, rs4838767 (Table 4) . p-Values for 8 traits (RP01-RP07 and peak BrAC [PKRP]) reached a study-wide level of significance (p < 4.10 9 10
À5
). The observed effect of rs4838767 was strongest for RP04 (p = 2.00 9 10 À7 ) with the minor C allele relating to a lower BrAC; the beta calculated in QTDT = 2.205 and explained approximately 8% of variance in the RP04 BrAC. The effect of rs4838767 genotype on BACs and BrACs is illustrated in Fig. 2 . This SNP was also associated with later BrAC measurements (RP08, RP09) and breath alcohol absorption (BRAP). A second SNP in CYP2E1 (rs4646976) was associated with 8 of these traits but to a lesser degree. A grouping of 6 SNPs on chromosome 17 near SLC25A11 in moderate to complete LD (r 2 = 0.7 to 1.0) was related to early breath alcohol readings and all the breath alcohol summary measures. This grouping included the nonsynonymous rs238239 polymorphism in ENO3 that codes for an alanine to valine codon change. Two SNPs in or near CAT and ACSS1 and 1 SNP each in ALDH1A1, MDH2, and GOT2 were associated with at least 1 breath alcohol trait with a p-value <0.005. Finally, the nonsynonymous SNP rs2298316 codes for an arginine to glutamate codon change in CNNM1 (near GOT1) and was most associated with peak BrAC (p = 0.003).
Multivariate Analyses
Given the (i) high correlation between the BAC and BrAC readings throughout the alcohol challenge and (ii) that the strongest allelic associations with variation in BACs or BrACs tended to be either with early or late stages of alcohol metabolism, we used a multivariate approach to search for SNPs that acted on general blood or breath alcohol metabolism (all times, LP1-LP6 or RP01-RP10) or SNPs that acted early (LP1-LP3 or RP01-RP05) or late (LP4-LP6 or RP06-RP10) in the time course of blood or breath alcohol metabolism. The strongest evidence of association with blood alcohol phenotypes was observed with SNPs located near or within GOT1 on chromosome 10. One SNP upstream of GOT1 (rs2490286) reached study-wide significance for general blood alcohol metabolism (multivariate p = 0.000040) and was also associated with late blood alcohol metabolism but to a lesser extent (multivariate p = 0.0019). Similar patterns of association were observed with rs2494654 (0.000057 and 0.00026, respectively) and rs2494652 (0.00018 and 0.0011). Two SNPs downstream of GOT1 (intergenic rs10748774 and rs6584273 in CNNM1) and an intronic SNP in ALDH1A1 (rs647880) were also nominally associated with general blood alcohol metabolism. With respect to breath alcohol metabolism, the most associated SNPs were located in CYP2E1 and ACSS1: rs4838767 in the promoter of CYP2E1 was associated with general BrAC levels (multivariate p = 0.00075), the intronic CYP2E1 SNP rs4646976 was most associated with late BrAC levels (multivariate p = 0.00092), and the intronic ACSS1 SNP (rs4813543) was strongly associated with late BrACs (multivariate p = 0.000041) but not associated with early BrAC levels (multivariate p = 0.714). Multivariate association results for all SNPs and phenotypes are presented in Table S6 and Fig. S4 . 
DISCUSSION
The object of our study was to identify genetic variants that modulate interindividual variation in the absorption and elimination of EtOH. This is carried out in the context of an alcohol metabolism pathway that includes both the metabolism of the carbon skeleton of EtOH and includes gene products that influence the activity of the malate-aspartate shuttle and rates of mitochondrial NADH reoxidation (Fig. 1) . We have previously shown that significant heritability exists for peak blood alcohol (0.62) and rate of elimination (0.49) in our sample (Martin et al., 1985) . Linkage and functional studies have pointed toward the role of genetic variation in the ADH cluster and ALDHs (Agarwal and Goedde, 1992; Birley et al., 2005 ) and association studies have followed up on these findings indirectly by studying the consequences of differing alcohol metabolism, namely subjective feeling of drunkenness, excessive alcohol consumption, or alcohol dependence (Chen et al., 2009; Dickson et al., 2006; Edenberg et al., 2006; Macgregor et al., 2009; Quertemont, 2004) . However, most pharmacogenetic studies of alcohol metabolism have focused on a small set of variants in ADH1B (Arg48His/rs1229984 and Arg369Cys/ rs2066702), ADH1C (Ile349Val/rs698 and Arg271Gln/ rs1693482), and ALDH2 (ALDH2*2/rs671). The role of genes that function in parallel (CYP2E1 and CAT) or downstream of ADHs and ALDH has, for the most part, not been studied with respect to variation in alcohol metabolism. Therefore, we have comprehensively tested for allelic association between 950 SNPs spanning 14 genes in the alcohol metabolism pathways with a timed series of BAC and BrAC measurements in 352 twins who participated in an alcohol challenge experiment. SNP genotype data were generated from both in-house genotyping and imputation of GWAS genotype data. It is noted that in our data set of 118 SNPs with both in-house generated and imputed GWAS genotypes, discordance rates were on average 2.4% with 4 SNPs (1 in CYP2E1 and 3 in ACSS1) showing discordance rates higher than 10%.
While multiple allelic associations (p < 0.005) between the tested SNPs and blood or breath alcohol phenotypes were observed in our sample, the only study-wide significant associations were observed with a promoter SNP in CYP2E1 (rs4838767). This SNP was genotyped on the Sequenom MassARRAY platform and the assay cluster plot and representative genotype spectrums are given in Fig. S5 . Association with rs4838767 was strongest with earlier BrACs (RP01-RP06) and peak BrAC (PKRP), with only suggestive or nominal association with later BrACs and the rate of breath alcohol elimination (BREP). The strongest association was between rs4838767 and RP04 (p = 2.0 9 10 À7 ) explaining~8% of RP04 phenotypic variance. This SNP was also most strongly associated with early BACs (LP1-LP3) and the peak BAC (PKLP).
The rs4838767 result, however, should be interpreted in the context of several limitations. First, the MAF for rs4838767 is low (~0.9%) in the twin sample where all phenotypes and covariates are available; only 6 heterozygote A/C twins and no homozygote C/C individuals were observed. However, this issue will be encountered in any allelic association analysis of low-MAF SNPs. We therefore obtained empirical p-values for rs4838767 at each phenotype by conducting 10,000 or 100,000 simulations in MERLIN (Table  S7 ). The simulate option in MERLIN results in data sets in which SNP data are simulated under the null hypothesis of no linkage or association with observed phenotypes while phenotypic measurements, including covariates, are preserved. We report study-wide significant empirical p-values for RP01, RP02, RP05, and RP06 but p-values smaller than those reported for RP03, RP04, and PKRP were not observed following 100,000 simulations. Second, the association finding may be affected by 1 opposite sex DZ female twin ("Twin 2a DZOS" in Fig. 2 ) who exhibited low alcohol concentrations throughout the course of the experiment. When this twin was excluded, the best p-value of association was 0.0002 with RP04. Third, the MAF is higher in nonEuropean populations (ranging from 8 to 17% in the Asian and African HapMap samples). In the ACTS sample, the heterozygote MZ twin pair ("Twin 1a MZM" and "Twin 1b MZM" in Fig. 2) reported Egyptian ancestry for all grandparents. When association analyses were rerun excluding this twin pair, the significance of association remained studywide significant for RP01-RP05 and PKRP (the p-value for RP04 was 2.0 9 10 À5 ). Nevertheless, CYP2E1 is a major component of the MEOS which oxidizes up to 10% of EtOH consumed. Furthermore, CYP2E1 contributes up to 60% of EtOH metabolism in heavy drinkers as the enzyme has a higher Km for alcohol than ADH and its activity is induced by chronic alcohol ingestion (Lands, 1998; Lieber, 1994; Tanaka et al., 2000) . A recent study (Webb et al., 2011) reported both linkage and association between CYP2E1 and the level of response to alcohol with the strongest association observed between a promoter SNP, rs10776687, and Subjective High Assessment Scale score. Two other CYP2E1 SNPs that many association studies have genotyped were included in the current study: CYP2E1*5B (constituting rs2031920 and rs3813867) in the promoter and CYP2E1*1B/rs2070676 in intron 7. CYP2E1*5B has been reported to affect transcription activity of the gene (Hayashi et al., 1991; Watanabe et al., 1994) and enhance both alcohol metabolism and risk for alcohol dependence in Mexican-Americans (Konishi et al., 2003) . Similarly, rs2070676 has been associated with increased activity of CYP2E1 in vivo (Haufroid et al., 2001 ). We did not observe association between the 4 SNPs described above and any phenotypes tested in our study (p-values > 0.05), with low LD (rs2070676, r 2 = 0.116) or no LD observed between rs4838767 and these SNPs. However, previously reported associations with these SNPs have been inconsistent and inconclusive, possibly due to phenotypic and population differences. It has also been suggested that CYP2E1 activity is higher in smokers than nonsmokers (Lucas et al., 1995; Schoedel and Tyndale, 2003) . While participants were not prevented from smoking during the experimental period, smoking history at the time of the alcohol challenge is available for 411 of the 412 twins: 154 were current smokers, 68 nonsmokers, and 189 ex-smokers. To test for a possible effect of current smoking on alcohol metabolism, secondary analyses of the CYP2E1 SNPs were performed in which current smoker status (Yes/No) was also included as a covariate. No change in the level or pattern of association was observed (data not shown).
While no other SNP-phenotype associations were studywide significant, there are suggestive patterns of findings that should be followed up in other cohorts as it would be unwise to dismiss the possibility of a true effect. We have low statistical power to detect an association at the study-wide level in our small sample, and the significance threshold of 4.01 9 10 À5 does not take into account the strong prior probability of a true association between some of our genes (in particular CYP2E1) and traits of interest. The overall lack of study-wide significant findings may be because there is an upper limit in the effect size associated with any single SNP that can be detected with our comparatively small sample (N = 352). While we have 80% statistical power to detect the observed association between rs4838767 and RP04 in our study using a = 4.01 9 10 À5 (the study-wide significance threshold), the required sample size almost triples (N = 804) when the SNP effect size falls to 3% of the trait variance. Therefore, we cannot exclude associations of smaller effect. However, it should be noted that few alcohol challenge studies currently exist in the literature and also have small sample sizes owing to the practical difficulty in conducting largescale experiments. Other alcohol challenge studies include 297 adult males (Schuckit et al., 2004) , 7 MZ and 7 DZ twin pairs (Vesell, 1972) , 19 MZ and 21 DZ male twin pairs (Kopun and Propping, 1977) .
Turning to the suggestive associations, there is some evidence for a role of cytosolic ALDH (ALDH1A1) in alcohol metabolism, with SNPs in this gene influencing all measurements of BAC and the peak BAC. ALDH1A1 has previously been reported to be associated with several alcohol-related phenotypes including alcohol consumption levels and alcohol dependence risk in Finns (Lind et al., 2008; Liu et al., 2010) and Southwest California Indians (Ehlers et al., 2004) . Next, 5 intronic SNPs in CAT (effectively 1 SNP owing to being in complete LD) were the only SNPs tested that achieved a level of significance <0.005 with the rate of blood alcohol elimination in our study. A CAT promoter SNP was most associated with the rate of breath alcohol absorption and peak BrAC. Finally, a series of SNPs located near SLC25A11 (a malate carrier in the malate-aspartate NADH shuttle) on chromosome 17 are associated with aspects of blood and breath alcohol metabolism, including a nonsynonymous coding SNP in ENO3 that is primarily associated with the rate of blood alcohol absorption and breath alcohol elimination. The role of ENO3 in alcohol metabolism is unclear as it functions in skeletal muscle and glycogen storage, and it was not selected a priori as a candidate gene for this study (Comi et al., 2001) .
Finally, we used a multivariate approach (Ferreira and Purcell, 2009) to search for polymorphisms with effects on multiple blood or breath alcohol traits that could have been missed in our main analysis. One SNP, rs2490286, upstream of the glutamic-oxaloacetic transaminase 1 (GOT1) reached study-wide significance for overall blood alcohol metabolism (Table S6 ). This SNP was not associated with any univariate BAC or BrAC measure in the main analysis but did show borderline association with the rate of blood alcohol elimination (p = 0.0068). GOT1 is an intriguing candidate gene which has recently been implicated in the level of response to alcohol in a GWAS utilizing 3 variables measured in an alcohol challenge (Joslyn et al., 2010) .
In conclusion, to study the genetics of alcohol metabolism it is important to test for effects of variation not only in the well-studied ADH and ALDH2 genes, but in additional genes/pathways involved in the metabolism of EtOH, co-factors (NAD + /NADH), and breakdown products (acetaldehyde). We suggest that variants that influence alcohol metabolism can be further studied in other alcohol cohorts where their effect on alcohol consumption, and subsequently risk for alcohol dependence, can be investigated. We did not find strong evidence that variation in genes metabolizing the carbon backbone of acetate or in mechanisms for regenerating NAD from NADH or the metabolism of acetaldehyde is rate-limiting in alcohol metabolism in our population. However, we did observe suggestive patterns of association with variants in ALDH1A1 and on chromosome 17 near SLC25A11 for aspects of blood and breath alcohol metabolism. Finally, while we lack power to observe small sizes of effect in our sample, we can conclude that regulatory sequences in the promoter of CYP2E1 may play a role in the preabsorptive metabolism of alcohol; however, more samples are required to validate this finding.
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